# A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

> **NCT06303570** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 19 (actual)

## Conditions studied

- Dercum's Disease

## Interventions

- **DRUG:** CBL-514 injection
- **DRUG:** 0.9% Sodium chloride

## Key facts

- **NCT ID:** NCT06303570
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-27
- **Primary completion:** 2026-03-23
- **Final completion:** 2026-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06303570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06303570, "A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06303570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*